An essential receptor for adeno-associated virus infection
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors are currently the leading candidates for virus-based gene therapies because of their broad tissue tropism, non-pathogenic nature and low immunogenicity. They have been successfully used in clinical trials to treat hereditary diseases such as haemophilia B (ref. 2), and have been approved for treatment of lipoprotein lipase deficiency in Europe. Considerable efforts have been made to engineer AAV variants with novel and biomedically valuable cell tropisms to allow efficacious systemic administration, yet basic aspects of AAV cellular entry are still poorly understood. In particular, the protein receptor(s) required for AAV entry after cell attachment remains unknown. Here we use an unbiased genetic screen to identify proteins essential for AAV serotype 2 (AAV2) infection in a haploid human cell line. The most significantly enriched gene of the screen encodes a previously uncharacterized type I transmembrane protein, KIAA0319L (denoted hereafter as AAV receptor (AAVR)). We characterize AAVR as a protein capable of rapid endocytosis from the plasma membrane and trafficking to the trans-Golgi network. We show that AAVR directly binds to AAV2 particles, and that anti-AAVR antibodies efficiently block AAV2 infection. Moreover, genetic ablation of AAVR renders a wide range of mammalian cell types highly resistant to AAV2 infection. Notably, AAVR serves as a critical host factor for all tested AAV serotypes. The importance of AAVR for in vivo gene delivery is further highlighted by the robust resistance of Aavr(-/-) (also known as Au040320(-/-) and Kiaa0319l(-/-)) mice to AAV infection. Collectively, our data indicate that AAVR is a universal receptor involved in AAV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The peptide insertion at position R588 in R100 sterically prohibits the close proximity between R585 and R588 required for heparan sulfate binding ( Fig. 5 B), suggesting a plausible mechanism for enhanced transit through the heparan sulfate-rich ILM barrier.”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Maxfield, F. R., & McGraw, T. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1315 · Cited by 1,729
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Ebola virus entry requires the cholesterol transporter Niemann–Pick C1
Carette, J. E., Raaben, M., Wong, A. C., Herbert, A. S., Obernosterer, G., Mulherkar, N., Kuehne, A. I., Kranzusch, P. J., Griffin, A. M., Ruthel, G., et al. (2011) · Nature · doi:10.1038/nature10348 · Cited by 1,303
Self-citationMannose 6-phosphate receptors: new twists in the tale
Ghosh, P., Dahms, N. M., & Kornfeld, S. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1050 · Cited by 1,086
A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells
Campeau, E., Ruhl, V. E., Rodier, F., Smith, C. L., Rahmberg, B. L., Fuss, J. O., Campisi, J., Yaswen, P., Cooper, P. K., & Kaufman, P. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006529 · Cited by 964
Cited by
Items 501–524 of 524
Modulating receptor interactions in retargeted AAV vectors
Silveria, M., Kumi, G. S., & Chapman, M. S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.024
Self-citationShang, L., Du, S., Liu, Y., Li, L., Wu, X., Yuan, Y., Jin, C., Mi, Q., Wang, Y., Shi, X., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70116
“Additionally, TM9SF2 has emerged in several large ‐ scale screens as a candidate factor involved in viral infection [40, 52, 53].”
A receptor-Fc based SFV replicon Trim-Away platform for targeted viral protein degradation
Han, Y., Dong, Q., Tian, Z., Wang, X. G., Wang, P., Liu, Q., Liu, Y., Guo, Q., & Zhang, S. (2026) · Virology Journal · doi:10.1186/s12985-026-03235-w
“Because AAV capsid proteins VP1, VP2, and VP3 share the conserved VP3 structural core recognized by AAVR [28, 29], the receptor decoy effectively mediates their simultaneous degradation.”
AAV delivered lysosome-targeting chimeras mediate sustained antibody depletion in vivoPreprint
Yang, J. L., Loh, K. Y., Espinoza, C. R. S., Schuster, D., Yamada‐Hunter, S. A., Labanieh, L., Sotillo, E., Mackall, C. L., Deisseroth, K. A., & Bertozzi, C. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.05.736665
“When injected into the murine tail vein, AAV8 typically infects many cell types (most prominently liver hepatocytes 36 ) and drives long-term transcription and translation of the transgene 37,38,39 (Fig.”
Large, E. E., Mensah, I., Kumi, G. S., & Chapman, M. S. (2026) · Viruses · doi:10.3390/v18070744 · Cited by 1
“AAV2 was instrumental in the discovery and characterization of a human proteinaceous AAV entry receptor (AAVR) [8].”
Self-citationOlarewaju, O., Bentler, M., Breuer, J., Alioglu, F., Grabowski, A., Prosche, A., Sami, H., Ogris, M., & Büning, H. (2026) · Human Gene Therapy · doi:10.1177/10430342261465461
“29 Compared to AAVR-WT cell lines, we observed severely reduced ef fi ciency in trans-ductions for all tested capsids (Supplementary Fig.”
Age outweighs route for AAV-PHP.eB transgene distribution via inner ear delivery
Han, S., Zhou, Y., Tang, H., Hu, S. W., Geng, G., Chen, Z., Zhang, S., Tang, H., Li, H., Jiang, Q., et al. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02191-w
A novel adeno-associated viral vector derived from human spleen isolate AAV.hu.S17
Guo, W., Sun, J., Wang, F., Nan, X., Rao, X., Feng, X. N., Zhang, T. B., Jin, F., Wang, Q., Chen, Y., et al. (2026) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2026.100773
“34 Over 50 capsid amino-acid substitutions are clustered within five contiguous hypervariable regions (VR-IV to VR-VIII) of AAV.hu.”
Sakamoto, K., Yoshida, K., Tsunekawa, Y., Mendoza, N. A. G., Komaki, Y., Onodera, A., & Okada, T. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201830
“While AAVR has been extensively characterized as a critical entry factor for multiple AAV serotypes, 10,13,14 our findings extend this role to the production aspect, where the same receptor-mediated interaction can affect the amount of vector remaining in the culture supernatant.”
Jereb, S., D’Alessandro, L. R., Morshed, N., Chen, M., Sartore, R., Han, Z., McKinney, J. E., Brauer, P. P., Harvey, J. W., Demers, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.05.739854
“AAV particles, which carry a single-stranded DNA genome, are endocytosed and trafficked through endolysosomal vesicles and the trans-Golgi network, then escape into the cytosol and enter the nucleus (Nonnenmacher & Weber, 2011; Pillay et al., 2016).”
Milagros, S., Pérez‐Martínez, D., Salazar-Diaz, S., de Erenchun, P. R.-R., Nicolao, M., Carte, B., Méndez, M., Echevarria, B., Reichardt, N., & Aldabe, R. (2026) · Research Square · doi:10.21203/rs.3.rs-10369568/v1
Rothschild‐Gronau, C., Borchert, P., Radukic, M. T., Haverkamp, L., Coras, R., Simon, M., & Müller, K. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-62481-8
Kubek-Luck, K., Velazquez, J. G., Yao, X., Gabriels, J., Hsu, C., Arora, S., Bontadelli, L., Gilbart, Y., Aihara, F., Li, H., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.024
AAV capsid-based nanocarriers encapsulating inorganic nanoparticles for targeted delivery
Sonnenschein, N., Lim, L., & Park, J. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb01266c
O’Hara-Wright, M., Lim, B. Y., Mangala, M. M., Kaiser, V., Wong, E., Aubin, D., Nemeruck, V., Reynisson, H., Doroudian, F., Chan, O. P. Y., et al. (2026) · Gene Therapy · doi:10.1038/s41434-026-00642-0
Decoding Nonlinearities in AAV-Based Gene Therapy Using PBPK Modelling
Rajwade, A., Liu, S., Kumar, M., & Shah, D. K. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01285-0
“Both AAV8 and AAV9 share majority of receptors to get into the cell including AAVR (AAV receptor) and Laminin receptor (31, 32).”
Yu, Z., Li, Y., Zhang, Z., & Yin, R. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1901875
“…Goertsen et al., 2022; Chen et al., 2023; Santoscoy et al., 2024), while the final therapeutic profile is shaped by the combined effects of capsid, regulatory elements, payload, dose and host context (Pillay et al., 2016; Dimidschstein et al., 2016; Ling et al., 2022, 2023; Gleichman et al., 2023).”
Nanobody-Functionalized AAV achieves Promoter-independent Neuronal Targeting in the CNS åPreprint
Extross, A., de Velasco, E. M. F., He, Y., Wickman, K., & Schmidt, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.18.752817
“Productive transduction by most serotypes further depends on the universal proteinaceous receptor AAVR (KIAA0319L), which couples initial glycan attachment to cellular entry 6 .”
Controllable gene delivery via masked adeno-associated viral vectors
Zeng, Z., Chang, L., Wang, J., Liu, Y., Wang, X., Sun, Y., Zuo, Y., Xiaoyu, H., Wang, Y., Gu, Z., et al. (2026) · Nature Materials · doi:10.1038/s41563-026-02724-1 · Cited by 1
Cross‐Neutralizing and Broadly Neutralizing Human Antibodies Against Nonenveloped Viruses
Marchand, S., Taouli, S., & McIlroy, D. (2026) · European Journal of Immunology · doi:10.1002/eji.70290
“Attachment is followed by internalization mediated by the trans-membrane AAVR protein, which is the common entry receptor for all AAV serotypes [ 26 ].”
Majewska, A., Siejda, K. W., Kowalec, M., Aleksandrowicz, K., Panchuk, Y., Rogala, M. M., Pianka, K., Minich, A., Jarocka, W., Walędziak, M. S., et al. (2026) · Viruses · doi:10.3390/v18101134
“More recently, AAVR/KIAA0319L was identified by unbiased genetic screening as a critical receptor for AAV2 infection, and AAVR loss strongly reduces AAV2 transduction across multiple mammalian cell types [55].”
Gene Therapy for Osteoarthritis: Viral and Non-Viral Delivery Strategies
Zhang, M., Mohess, J., Cheung, J., Du, Q., Qiu, J., & Wang, J. (2026) · Viruses · doi:10.3390/v18101151
“…factors such as sialic acids (SA) or heparan sulfate proteoglycans (HSPG) and engages entry receptors, such as AAV receptor (AAVR/KIAA0319L) [20,21], which facilitate internalization via the clathrin-independent carrier/glycosylphosphatidylinositol-enriched endocytic compartment (CLIC/GEEC)…”
Khalil, M., Bisignani, M., & Kandler, K. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1946992
CNS targeted AAV gene therapies: Recent advances and clinical insights
Brown, B. P., Lewis, R. W., Jr., & Davidson, B. L. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103118 · Cited by 1
Metadata
- Authors
- Pillay, S., Meyer, N. L., Puschnik, A. S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L. T., Wosen, J. E., Nagamine, C. M., Chapman, M. S., & Carette, J. E.
- Affiliations
- Stanford Medicine (US)
- Oregon Health & Science University (US)
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Chapman, M. S.
- Carette, J. E.
- ORCID
- Venue
- Nature
- Published
- 2016-01-27
- Volume
- 530
- Issue
- 7588
- Pages
- 108-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4962915
- OpenAlex
- W2266837556
- Cited by
- 532
- References
- 33
- Citations by year
- 2026: 58 · 2025: 51 · 2024: 63 · 2023: 60 · 2022: 36 · 2021: 47 · 2020: 57 · 2019: 50 · 2018: 43 · 2017: 37 · 2016: 28
- FWCI
- 43.04
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-09-28)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5u19ai109662-05)
- National Institute of General Medical Sciences (R01GM066875)
- National Institute of Allergy and Infectious Diseases (DP2AI104557, U19-AI109662)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- adeno-associated virus, AAV receptor, AAV2, viral entry, host factors, endocytosis, AAV serotypes, gene therapy vectors, viral gene delivery
- MeSH terms
- Dependovirus, Animals, Antibodies, Cell Line, Endocytosis, Female, Humans, Male, Parvoviridae Infections, Receptors, Cell Surface, Receptors, Virus, Genetic Therapy, Gene Deletion, trans-Golgi Network, Mice, Virus Internalization, Viral Tropism, Host Specificity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.